Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease

[1]  Sterling C. Johnson,et al.  Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology , 2016, Nature Communications.

[2]  Olivier Rouaud,et al.  Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease. , 2016, The Journal of clinical psychiatry.

[3]  Byeong-Chae Kim,et al.  Effects of donepezil on brain morphometric and metabolic changes in patients with Alzheimer's disease: A DARTEL-based VBM and (1)H-MRS. , 2016, Magnetic resonance imaging.

[4]  S. Lehéricy,et al.  Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease , 2016, Neuropharmacology.

[5]  Lea T Grinberg,et al.  Cognitive Correlates of Basal Forebrain Atrophy and Associated Cortical Hypometabolism in Mild Cognitive Impairment. , 2016, Cerebral cortex.

[6]  H. Möller,et al.  Effects of rivastigmine on visual attention in subjects with amnestic mild cognitive impairment: A serial functional MRI activation pilot-study , 2016, Psychiatry Research: Neuroimaging.

[7]  Enrica Cavedo,et al.  Efficacy of lifestyle interventions on clinical and neuroimaging outcomes in elderly , 2016, Ageing Research Reviews.

[8]  Shaomin Li,et al.  Progress in mechanisms of acetylcholinesterase inhibitors and memantine for the treatment of Alzheimer's disease , 2015 .

[9]  Georg M. Kerbler,et al.  Basal Forebrain Atrophy Contributes to Allocentric Navigation Impairment in Alzheimer’s Disease Patients , 2015, Front. Aging Neurosci..

[10]  A. Maubon,et al.  Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease , 2015, Alzheimer's & Dementia.

[11]  C. Itsiopoulos,et al.  Omega-3 Fatty Acids in Early Prevention of Inflammatory Neurodegenerative Disease: A Focus on Alzheimer's Disease , 2015, BioMed research international.

[12]  Brian T. Gold,et al.  Lifelong bilingualism and neural reserve against Alzheimer's disease: A review of findings and potential mechanisms , 2015, Behavioural Brain Research.

[13]  H. Gertz,et al.  Early neurone loss in Alzheimer’s disease: cortical or subcortical? , 2015, Acta neuropathologica communications.

[14]  Olivier Salvado,et al.  Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease , 2014, NeuroImage: Clinical.

[15]  Stefan J. Teipel,et al.  Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects , 2014, Alzheimer's & Dementia.

[16]  P. L. Fernández,et al.  Microglia receptors and their implications in the response to amyloid β for Alzheimer’s disease pathogenesis , 2014, Journal of Neuroinflammation.

[17]  Stefan Teipel,et al.  Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease , 2014, Neurobiology of Aging.

[18]  H. Heinsen,et al.  Association of basal forebrain volumes and cognition in normal aging , 2014, Neuropsychologia.

[19]  M. Mesulam,et al.  Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease , 2013, The Journal of comparative neurology.

[20]  H. Heinsen,et al.  Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer's disease , 2013, Neurobiology of Aging.

[21]  J. Molinuevo,et al.  Donepezil Treatment Stabilizes Functional Connectivity During Resting State and Brain Activity During Memory Encoding in Alzheimer’s Disease , 2013, Journal of clinical psychopharmacology.

[22]  Gerard R. Ridgway,et al.  Symmetric Diffeomorphic Modeling of Longitudinal Structural MRI , 2013, Front. Neurosci..

[23]  H. Heinsen,et al.  Atrophy of the Cholinergic Basal Forebrain Over the Adult Age Range and in Early Stages of Alzheimer's Disease , 2012, Biological Psychiatry.

[24]  J. Morillas-Ruiz,et al.  A Review: Inflammatory Process in Alzheimer's Disease, Role of Cytokines , 2012, TheScientificWorldJournal.

[25]  N. Schuff,et al.  An MRI substudy of a donepezil clinical trial in mild cognitive impairment , 2011, Neurobiology of Aging.

[26]  Chunming Xie,et al.  Recovery of hippocampal network connectivity correlates with cognitive improvement in mild alzheimer's disease patients treated with donepezil assessed by resting‐state fMRI , 2011, Journal of magnetic resonance imaging : JMRI.

[27]  Harald Hampel,et al.  The cholinergic system in mild cognitive impairment and Alzheimer's disease: An in vivo MRI and DTI study , 2011, Human brain mapping.

[28]  M. Sabbagh,et al.  Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer’s disease , 2011, Acta Neuropathologica.

[29]  B. Winblad,et al.  Alzheimer's disease: clinical trials and drug development , 2010, The Lancet Neurology.

[30]  K. Amunts,et al.  Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer's disease. , 2010, Cerebral cortex.

[31]  H. Heinze,et al.  Basal forebrain integrity and cognitive memory profile in healthy aging , 2010, Brain Research.

[32]  P. Crane.  DONEPEZIL TREATMENT OF PATIENTS WITH MCI: A 48-WEEK RANDOMIZED, PLACEBO- CONTROLLED TRIAL , 2009, Neurology.

[33]  Alexander Hammers,et al.  Automatic segmentation of the hippocampus and the amygdala driven by hybrid constraints: Method and validation , 2009, NeuroImage.

[34]  C. Jack,et al.  Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI , 2008, Neurobiology of Aging.

[35]  C. Jack,et al.  MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers , 2008, Brain : a journal of neurology.

[36]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[37]  L. Flicker,et al.  Donepezil for mild cognitive impairment. , 2006, The Cochrane database of systematic reviews.

[38]  Stefan J. Teipel,et al.  Effects of donepezil on cortical metabolic response to activation during 18FDG-PET in Alzheimer’s disease: a double-blind cross-over trial , 2006, Psychopharmacology.

[39]  M. Sabbagh,et al.  Do cholinergic therapies have disease-modifying effects in Alzheimer’s disease? , 2006, Alzheimer's & Dementia.

[40]  H. Möller,et al.  Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. , 2005, Brain : a journal of neurology.

[41]  Hiroaki Kazui,et al.  Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? , 2005, The American journal of psychiatry.

[42]  R. Dolan,et al.  Effects of Cholinergic Enhancement on Visual Stimulation, Spatial Attention, and Spatial Working Memory , 2004, Neuron.

[43]  Xin Yu,et al.  Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. , 2003, The American journal of psychiatry.

[44]  Hirofumi Sakurai,et al.  Atrophy of the Substantia innominata on Magnetic Resonance Imaging Predicts Response to Donepezil Treatment in Alzheimer’s Disease Patients , 2003, Dementia and Geriatric Cognitive Disorders.

[45]  M. Luca,et al.  ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model , 2002, European Neuropsychopharmacology.

[46]  R. Kawashima,et al.  The Role of the Basal Forebrain in Episodic Memory Retrieval: A Positron Emission Tomography Study , 2002, NeuroImage.

[47]  G. Wilcock,et al.  The cholinergic hypothesis of Alzheimer’s disease: a review of progress , 1999, Journal of neurology, neurosurgery, and psychiatry.

[48]  R. Quirion,et al.  β-Amyloid peptides as direct cholinergic neuromodulators: a missing link? , 1998, Trends in Neurosciences.

[49]  R. Nieuwenhuys,et al.  Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer's disease , 1990, Neurobiology of Aging.

[50]  M M Mesulam,et al.  Human reticular formation: Cholinergic neurons of the pedunculopontine and laterodorsal tegmental nuclei and some cytochemical comparisons to forebrain cholinergic neurons , 1989, The Journal of comparative neurology.

[51]  C. Geula,et al.  Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: Observations based on the distribution of acetylcholinesterase and choline acetyltransferase , 1988, The Journal of comparative neurology.

[52]  T. Arendt,et al.  Correlation between cortical plaque count and neuronal loss in the nucleus basalis in Alzheimer's disease , 1984, Neuroscience Letters.

[53]  M. Mesulam,et al.  Atlas of cholinergic neurons in the forebrain and upper brainstem of the macaque based on monoclonal choline acetyltransferase immunohistochemistry and acetylcholinesterase histochemistry , 1984, Neuroscience.

[54]  A. Levey,et al.  Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (Substantia innominata), and hypothalamus in the rhesus monkey , 1983, The Journal of comparative neurology.

[55]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[56]  E K Perry,et al.  Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. , 1978, British medical journal.

[57]  Stefan Klöppel,et al.  Subregional basal forebrain atrophy in Alzheimer's disease: a multicenter study. , 2014, Journal of Alzheimer's disease : JAD.

[58]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[59]  K. Arai,et al.  Anti-inflammatory action of donepezil ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopathy mouse model. , 2010, Journal of Alzheimer's disease : JAD.

[60]  A. Akaike,et al.  Donepezil potentiates nerve growth factor-induced neurite outgrowth in PC12 cells. , 2007, Journal of pharmacological sciences.

[61]  H. Hampel,et al.  Assessing Therapeutic Efficacy in a Progressive Disease , 2006, CNS drugs.

[62]  M. Mesulam,et al.  The cholinergic innervation of the human cerebral cortex. , 2004, Progress in brain research.

[63]  E. Giacobini.  Do Cholinesterase Inhibitors Have Disease-Modifying Effects in Alzheimer’s Disease? , 2001, CNS drugs.